References
- Antolin, I., Mayo, J. C., et al. (2002). Protective effect of melatonin in a chronic experimental model of Parkinson’s disease. Brain Res 943:163–173.
- Ballabh, P., Braun, A., Nedergaard, M. (2004). The blood-brain barrier: an overview. Structure, regulation, and clinical implications. Neurobiol Dis 16:1–13.
- Beal, M. F. (1992). Mechanisms of excitotoxicity in neurologic diseases. FASEB J 6:3338–3344.
- Carafa, M., Santucci, E., et al. (1998). Preparation and properties of new unilamellar non-ionic/ionic surfactant vesicles. Int J Pharm 160:51–59.
- Chonn, A., Cullis, P. R. (1995). Recent advances in liposomal drug-delivery systems. Curr Opin Biotechnol 6:698–708.
- Da Prada M., Keller, H., et al. (1984). The pharmacology of Parkinson’s disease: basic aspects and recent advances. Experientia 40:165–172.
- Di Stefano A., Carafa, M., et al. (2004). Evaluation of rat striatal L-DOPA and DA concentration after intraperitoneal administration of L-DOPA prodrugs in liposomal formulation. J Contr Rel 99:293–300.
- Di Stefano A., Sozio, P., et al. (2006). Maleic- and fumaric-diamides of (O,O-diacetyl)-L-DOPA-methylester as anti-Parkinson prodrugs in liposomal formulation. J Drug Targ 14:652–661.
- Fresta, M., Puglisi, G., et al. (1993). CDP-choline entrapment and release from multilamellar and reverse-phase evaporation liposomes. Drug Dev Ind Pharm 19:559–585.
- Giannola, L. I., De Caro V., et al. (2008). Synthesis and in vitro studies on a potential dopamine prodrug. Pharmazie 63:704–710.
- Gregoriadis, G., Senior, J. (1984). Targeting of small unilamellar liposomes to the galactose receptor in vivo. Biochem Soc Trans 12:337–339.
- Gulati, M., Grover, M., et al. (1998). Lipophilic drug derivatives in liposomes. Int J Pharmaceut 165:129–168.
- Ho, N. F. H., Ganesan, M. G., et al. (1985). Mechanism of topical delivery of liposomally entrapped drugs. J Contr Rel 2:61–65.
- Moreno, M. M., Garidel, P., et al. (2009). The membrane-activity of ibuprofen, diclofenac, and naproxen: a physico-chemical study with lecithin phospholipids. Biochim Biophys Acta 1788:1296–1303.
- New, R. R. C. (1990). Liposomes: a practical approach ( pp 44–47). Oxford, UK: Oxford University Press.
- Patel M. M., Goyal B. R., et al. (2009). Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs 23:35–58.
- Sabín, J., Prieto, G., et al. (2009). Interactions between DMPC liposomes and the serum blood proteins HSA and IgG. J Phys Chem B 113:1655–1661.
- Scherrmann, J. M. (2002). Drug delivery to brain via the blood-brain barrier. Vasc Pharmacol 38:349–354.
- Semple, S. C., Chonn, A., Cullis, P. R. (1996). Influence of cholesterol on the association of plasma proteins with liposomes. Biochemistry 35:2521–2525.
- Stewart, J. C. M. (1980). Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem 104:10–14.
- Tolosa, E., Marti, M. J., et al. (1998). History of levodopa and dopamine agonists in Parkinson’s disease treatment. Neurology 50:S2–S10.
- Vadiei, K., Lopez-Berestein, G., et al. (1989). In vitro evaluation of liposomal cyclosporine. Int J Pharm 57:133–138.
- Zhigaltsev, I. V., Kaplun, A. P., et al. (2001). Liposomes containing dopamine entrapped in response to transmembrane ammonium sulfate gradient as carrier system for dopamine delivery into the brain of parkinsonian mice. J Liposome Res 11:55–71.